[A18-36] Olaparib (ovarian, fallopian tube, peritoneal cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 17.09.2018
Project no.:
A18-36
Commission:
Commission awarded on 05.06.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Patients with platinum-sensitive relapsed high-grade ovarian cancer
Serous epithelial ovarian cancer: hint of minor added benefit. Non-serous epithelial ovarian cancer: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant pages of the G-BA website: Nutzenbewertungsverfahren zum Wirkstoff Olaparib (neues Anwendungsgebiet: high-grade epitheliales Ovarialkarzinom, Eileiterkarzinom oder primäres Peritonealkarzinom) and Nutzenbewertungsverfahren zum Wirkstoff Olaparib (Aufhebung des Orphan-Drug-Status).
Federal Joint Committee (G-BA)
2018-12-06 A G-BA decision was published.